4DMedical
4DMedical is an Australian and United States-based medical technology company that develops software and imaging systems for quantitative regional lung-function assessment.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
4DMedical is a medical technology company operating in Australia and the United States, focused on measuring lung function through dynamic medical imaging and computational analysis. Its central technology, known as XV Technology, was developed to move beyond conventional imaging that primarily depicts lung anatomy. By analysing changes in X-ray or computed tomography images during breathing, the technology is designed to quantify regional lung motion and airflow across the lungs and throughout the respiratory cycle. The company’s principal software product is X-ray Velocimetry Lung Ventilation Analysis Software, commonly referred to as XV LVAS. It processes dynamic X-ray or fluoroscopic image sequences and uses proprietary algorithms derived in part from advanced aerodynamics and wind-tunnel imaging research. The resulting analysis generates quantitative information about regional ventilation and lung motion, typically presented to clinicians through reports containing colour-coded lung images and functional measurements. The intended value proposition is the identification of local or subtle functional abnormalities that may not yet be apparent from structural imaging alone. 4DMedical has also commercialised CT Lung Ventilation Analysis Software, or CT LVAS. This cloud-based product analyses non-contrast thoracic CT images acquired at inspiratory and expiratory phases. It is designed to use existing clinical imaging equipment and to fit into established radiology workflows, while providing regional information about pulmonary function. The company commercialises its software through a software-as-a-service model in which scans can be acquired using installed imaging systems and analysed remotely by 4DMedical. The company’s technology has applications across respiratory medicine, clinical research and the investigation of lung disease. One area of public interest has been the assessment of difficult-to-diagnose respiratory conditions among United States military veterans exposed to burn pits and other toxic substances. Following enactment of the United States PACT Act in 2022, 4DMedical worked with veteran and patient advocacy organisations and participated in research involving Vanderbilt University Medical Center and the Nashville Veterans Affairs Medical Center. These activities relate to the potential use of quantitative functional imaging alongside other clinical evidence; they do not by themselves establish a diagnosis or a universally accepted treatment pathway. In addition to software, 4DMedical has pursued dedicated imaging hardware. Through its wholly owned Australian Lung Health Initiative subsidiary, the company received Australian Federal Government funding to develop the XV Scanner, a purpose-built system intended to provide rapid, low-dose and contrast-free quantitative lung-function measurements for adults and children. The company also developed the Permetium preclinical scanner, a small-animal imaging system intended for research into regional pulmonary function, drug development and therapeutic testing. The underlying research originated from work associated with Andreas Fouras and researchers at Monash University. Fouras conceptualised four-dimensional X-ray imaging in 2005, and an initial XV Technology patent was filed in 2009. The research programme subsequently produced a body of peer-reviewed publications and patent activity. 4DMedical began as a private company and listed on the Australian Securities Exchange in August 2020 under the code 4DX. Its products remain subject to market-specific regulatory requirements, clinical adoption, reimbursement conditions and the company’s continuing commercial and research development.
History
4DMedical grew out of research led by biomedical engineer Andreas Fouras in collaboration with researchers associated with Monash University in Melbourne. The research sought to adapt imaging concepts used in aerodynamics and wind-tunnel analysis to the study of air movement through the lungs. Fouras conceptualised four-dimensional X-ray imaging in 2005, and the first patent associated with XV Technology was filed in 2009. The resulting approach combined fluoroscopy, image enhancement, computer vision and computational analysis to estimate lung motion and airflow during breathing. The technology was designed to address a limitation of conventional respiratory imaging: structural images can show the shape and condition of the lungs, but may provide limited information about how different regions function during the breathing cycle. XV Technology instead analyses motion over time and seeks to quantify regional ventilation. Its outputs can be assembled into three-dimensional, time-dependent representations of pulmonary function, allowing clinicians to examine differences between regions of the lung. The company was founded in 2013 and initially operated as a private enterprise under the 4DX identity. It developed a commercial model based largely on software and remote analysis rather than requiring every healthcare provider to purchase a new imaging platform. Under this model, patients can be scanned using existing equipment, after which 4DMedical processes the data through its analytical systems and returns a report for clinical review. The first major software product was XV LVAS, an X-ray-based system for non-invasive assessment of regional lung motion and airflow. The product received United States Food and Drug Administration clearance in May 2020 and was subsequently released in Australia after inclusion on the Australian Register of Therapeutic Goods in 2021. The company listed on the Australian Securities Exchange in August 2020 under the ticker 4DX, marking its transition from a private technology developer to a publicly traded medical technology business. 4DMedical later expanded its software portfolio with CT LVAS. Rather than requiring a dynamic fluoroscopic sequence, CT LVAS uses non-contrast thoracic CT images acquired during inspiratory and expiratory phases. Its cloud-based architecture is intended to work with existing CT infrastructure and provide additional functional analysis within established imaging workflows. The product entered the Australian market after ARTG listing in 2022. The company has also pursued applications outside routine clinical imaging. Its work with veteran advocacy organisations and research groups has focused in part on respiratory disease associated with military burn-pit exposure and other inhaled toxins. Studies involving Vanderbilt University Medical Center and the Nashville Veterans Affairs Medical Center have investigated relationships between XV LVAS findings and results from open lung biopsies. These studies form part of an ongoing research and validation effort rather than constituting a general clinical conclusion for all affected patients. Hardware development became another strand of the company’s strategy. Through the Australian Lung Health Initiative, a wholly owned subsidiary, 4DMedical received Australian Federal Government support through the Medical Research Future Fund to develop the XV Scanner. The proposed system is intended to provide dedicated, rapid, low-dose and contrast-free quantitative lung-function imaging for both adults and children. The Permetium preclinical scanner extends the technology into laboratory research, offering small-animal X-ray, three-dimensional CT and four-dimensional CT capabilities for studying pulmonary function and evaluating potential therapies. The company’s research base has been described as producing more than 100 peer-reviewed publications and more than 72 patents and patent applications. Its continuing development has centred on regulatory clearance, clinical validation, integration with installed imaging infrastructure and expansion from Australian origins into the United States. Product availability, indications, reimbursement and regulatory status remain market- and time-dependent.
- 2022
CT LVAS enters the Australian market
[1]CT LVAS was released in Australia following its listing on the Australian Register of Therapeutic Goods.
- 2021
XV LVAS is listed in Australia
[1]XV LVAS became available in Australia after being listed on the Australian Register of Therapeutic Goods.
- 2020
XV LVAS receives FDA clearance
[1]The X-ray Velocimetry Lung Ventilation Analysis Software received United States FDA clearance and was released to the U.S. market.
- 2020
ASX listing
[1]4DMedical listed on the Australian Securities Exchange in August under the ticker 4DX.
- 2013
4DMedical is founded
[1]The company was founded by Andreas Fouras to develop and commercialise dynamic lung-imaging and ventilation-analysis technology.
- 2009
First XV Technology patent is filed
[1]The first patent associated with the company’s XV Technology was filed during the underlying research programme.
- 2005
Four-dimensional X-ray imaging is conceptualised
[1]Andreas Fouras conceptualised an approach to four-dimensional imaging using X-rays as part of the research that later underpinned XV Technology.
Products and positioning
A respiratory medical-imaging technology brand positioned around quantitative, regional and dynamic assessment of lung ventilation and pulmonary function.
Respiratory imaging platform
XV Technology
XV Technology is 4DMedical’s proprietary platform for measuring regional lung motion and airflow from medical images. Its algorithms were adapted from advanced aerodynamics and wind-tunnel imaging research and are designed to analyse image changes over time during breathing. The platform supports quantitative, spatially resolved assessment of pulmonary ventilation rather than relying only on static anatomical appearance. It underpins the company’s clinical software and planned dedicated scanning systems.
X-ray lung ventilation analysis software · 2020
XV LVAS
X-ray Velocimetry Lung Ventilation Analysis Software is a non-invasive system for assessing regional lung motion and airflow. It analyses dynamic X-ray or fluoroscopic image sequences collected during normal tidal breathing and produces three-dimensional, time-dependent measurements of lung function. Reports can include colour-coded lung maps and quantitative indicators intended for clinical interpretation. The product received U.S. FDA clearance in 2020 and was later listed for Australian use in 2021.
Computed tomography lung ventilation analysis software · 2022
CT LVAS
Computed Tomography Lung Ventilation Analysis Software is a cloud-based product that analyses non-contrast thoracic CT images acquired at inspiratory and expiratory phases. It is designed to derive regional information about lung motion and airflow from existing CT equipment, potentially adding functional analysis without requiring a dedicated scanner. CT LVAS is intended to integrate with clinical imaging workflows and was listed for use in Australia in 2022.
Dedicated lung-function imaging system
XV Scanner
The XV Scanner is a dedicated lung-function imaging system under development through 4DMedical’s Australian Lung Health Initiative subsidiary. It is intended to use XV Technology to provide rapid, low-dose and contrast-free quantitative measurements of regional pulmonary function. The proposed system is designed for adults and children and aims to address limitations of conventional respiratory diagnostic tools by combining dedicated acquisition hardware with dynamic functional analysis.
Preclinical pulmonary imaging system
Permetium Preclinical Scanner
Permetium is a small-animal imaging system intended for preclinical research into regional pulmonary function. It can operate as an X-ray device, a three-dimensional CT scanner and a four-dimensional CT scanner, and is designed to work with XV Technology. By enabling repeated functional measurements in the same research subjects, the system is intended to support therapeutic and drug-development studies while potentially reducing the need for terminal experimental time points.
Marketing campaigns
- 2022Veterans’ burn-pit lung-disease research
United States
4DMedical worked with veteran advocacy groups, including Burn Pits 360, and research institutions on the use of non-invasive XV LVAS analysis in investigating respiratory disease among veterans exposed to burn pits and other toxic substances.
Outcome. Research at Vanderbilt University Medical Center and the Nashville Veterans Affairs Medical Center examined correlations between XV LVAS findings and open lung biopsy results. The work was presented as an ongoing research and validation effort.
Brand decisions
2022
Introduction of CT LVAS in AustraliaProduct launchBackground
The company expanded beyond dynamic X-ray analysis with a cloud-based product designed to use existing inspiratory and expiratory CT images.
Action taken
CT LVAS was listed on the Australian Register of Therapeutic Goods and released to the Australian market.
Aftermath
The product broadened 4DMedical’s respiratory imaging offering to include CT-based functional analysis.
2020
Commercial launch of XV LVAS in the United StatesProduct launchBackground
The company sought to commercialise its XV Technology through software that could analyse scans obtained using existing imaging equipment.
Action taken
4DMedical released XV LVAS after receiving U.S. FDA clearance in May 2020.
Aftermath
The clearance enabled the product’s entry into the U.S. market and supported the company’s software-as-a-service commercial model.
2020
Public listing on the ASXOtherBackground
After operating as a private company, 4DMedical pursued access to public capital markets and broader commercial development.
Action taken
The company listed on the Australian Securities Exchange in August 2020 under the code 4DX.
Aftermath
4DMedical became a publicly traded medical technology company.
- Development of dedicated lung-imaging hardwareStrategy
Background
4DMedical sought to extend XV Technology beyond software analysis performed on existing hospital imaging equipment.
Action taken
Through the Australian Lung Health Initiative, the company pursued the XV Scanner and developed the Permetium preclinical scanner.
Aftermath
The hardware programme expanded the company’s potential scope into dedicated clinical imaging and preclinical research, while the commercial and regulatory status of individual systems remains market dependent.
Recent events
Bosta secures $6.7 million Series A investment[3]
Egyptian e-commerce logistics startup Bosta secured $6.7 million in a Series A round led by Silicon Badia, with participation from 4DX, Plug and Play Ventures, Wealthwell VC, Khawarizmi VC and other investors.
4DMedical announces A$55.8 million IPO[4]
Reported:
4DMedical announced an IPO to raise $55.8 million by issuing 76.43 million shares priced at $0.73 each. The company said it anticipated trading on the ASX to begin on 14 August 2020.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/4dmedical · Editorial policy · How profiles are compiled